September 7, 2014 | Foam-based drugs developer Foamix announced that it expects to raise $71 million in its upcoming NASDAQ IPO, according to the company prospectus. Additionally, the company noted that it could raise up to $81 million if the underwriters exercise of their options, at a company value of $239 million, after money. The company plans to offer up 6 million shares at a price of between $10-$12 a piece. The underwriters for the offering, scheduled to take place on September 18, are Barclays Investment Bank, Cowen, Oppenheimer, and Maxim group.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
![](https://nocamels.com/wp-content/uploads/2018/02/INSIGHTEC-350x180.jpg)
Israeli Ultrasound Creator Collaborating On Neuroscience R&D In US
September 05, 2024
![The Weizmann Institute of Science. Photo via the Weizmann Institute of Science](https://nocamels.com/wp-content/uploads/2018/07/weizmann-350x252.jpg)
Weizmann In World’s Top 10 For Biomedical And Overall Research
September 05, 2024
![](https://nocamels.com/wp-content/uploads/2024/09/Depositphotos_75148477_L-350x228.jpg)
Israeli NGO Begins New Mental Health Training In Ukraine
September 04, 2024
![](https://nocamels.com/wp-content/uploads/2024/09/17123254699_79ff768811_ks-350x213.jpg)
Nonprofit Launches Loans For Stricken Northern Israel Businesses
September 04, 2024
Facebook comments